Table 1 Baseline characteristics of patients with EGC.
From: HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
|  | Total (n = 680) |
|---|---|
Age | 59.9 ± 11.8 |
Sex | |
Male | 456 (67.1%) |
Female | 224 (32.9%) |
Tumour size | 32.3 ± 19.4 |
Vertical location | |
UT | 145 (21.3%) |
MT | 236 (34.7%) |
LT | 299 (44.0%) |
Horizontal location | |
AW | 149 (21.9%) |
GC | 107 (15.7%) |
PW | 176 (25.9%) |
LC | 248 (36.5%) |
Gross type | |
Elevated | 109 (16.0%) |
Flat | 213 (31.3%) |
Depressed | 358 (52.6%) |
Depth of invasion | |
M | 343 (50.4%) |
SM | 337 (49.6%) |
Histology | |
WD | 76 (11.2%) |
MD | 240 (35.3%) |
PD | 132 (19.4%) |
SRC | 190 (27.9%) |
Mixed | 38 (5.6%) |
Mucinous | 2 (0.3%) |
Lymphoid stroma | 2(0.3%) |
Status of HER2 | |
Negative (0) | 200 (29.4%) |
Negative (1+) | 262 (38.5%) |
Equivocal (2+) | 182 (26.8%) |
Positive (3+) | 36 (5.3%) |
LVI | |
No | 540 (79.4%) |
Yes | 140 (20.6%) |
LN metastasis | |
No | 600 (88.2%) |
Yes | 80 (11.8%) |
